📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Vyriad

1.1 - Company Overview

Vyriad Logo

Vyriad

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage oncolytic virotherapies and gene therapy platforms, including Voyager-V1 (VSV-based oncolytic virotherapy in trials for multiple cancers), Measles-NIS (oncolytic measles virus encoding NIS for precision targeting and monitoring), oncolytic virus platforms using VSV and measles, in vivo gene therapy vectors, and engineered lentiviral vectors; conducts phase 1/2 clinical trials.

Products and services

  • Oncolytic Virus Platforms: Dual-virus (VSV and measles) platforms engineered to target and kill cancer cells while enhancing the immune response
  • Voyager-V1: VSV-based oncolytic virotherapy engineered for enhanced safety, efficacy, and traceability, currently being clinically tested for multiple cancer indications
  • Measles-NIS: Gene-encoded NIS oncolytic measles virus designed for precision targeting of cancer cells and monitoring virus delivery and infection using the human thyroidal sodium iodide symporter

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Vyriad

NextCure Logo

NextCure

HQ: United States Website
  • Description: Provider of biopharmaceutical discovery and development focused on next-generation immuno-oncology-based drugs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NextCure company profile →
VaxGen Logo

VaxGen

HQ: United States Website
  • Description: Provider of biopharmaceutical products in the United States.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full VaxGen company profile →
Arsanis Logo

Arsanis

HQ: Austria Website
  • Description: Provider of biopharmaceutical infectious disease treatments based on bacterial protein and carbohydrate antigens.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Arsanis company profile →
Cidara Therapeutics Logo

Cidara Therapeutics

HQ: United States Website
  • Description: Provider of drug-Fc conjugate therapeutics built on the Cloudbreak platform, which couples targeted small molecules and peptides to a human antibody fragment (Fc) to inhibit disease targets and engage the immune system; includes CD388, a Phase 2 DFC for preventing seasonal influenza A and B, and CBO421, an IND-enabling oncology DFC targeting CD73 to enhance anti-tumor immunity.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cidara Therapeutics company profile →
Adheron Therapeutics Logo

Adheron Therapeutics

HQ: United States Website
  • Description: Provider of biotechnology therapeutics that disrupt cell adhesion to treat a variety of diseases, based on pioneering work from Dr. Michael Brenner’s lab at Brigham and Women’s Hospital and Harvard Medical School, including work around Cadherin-11 (Cad-11), a cellular adhesive.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Adheron Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Vyriad

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Vyriad

2.2 - Growth funds investing in similar companies to Vyriad

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Vyriad

4.2 - Public trading comparable groups for Vyriad

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Vyriad

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Vyriad

What does Vyriad do?

Vyriad is a provider of clinical-stage oncolytic virotherapies and gene therapy platforms, including Voyager-V1 (VSV-based oncolytic virotherapy in trials for multiple cancers), Measles-NIS (oncolytic measles virus encoding NIS for precision targeting and monitoring), oncolytic virus platforms using VSV and measles, in vivo gene therapy vectors, and engineered lentiviral vectors; conducts phase 1/2 clinical trials.

Who are Vyriad's competitors?

Vyriad's competitors and similar companies include NextCure, VaxGen, Arsanis, Cidara Therapeutics, and Adheron Therapeutics.

Where is Vyriad headquartered?

Vyriad is headquartered in United States.

How many employees does Vyriad have?

Vyriad has 1,000 employees 🔒.

When was Vyriad founded?

Vyriad was founded in 2010 🔒.

What sector and industry vertical is Vyriad in?

Vyriad is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Vyriad

Who are the top strategic acquirers in Vyriad's sector and industry

Top strategic M&A buyers and acquirers in Vyriad's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Vyriad?

Top strategic M&A buyers groups and sectors for Vyriad include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Vyriad's sector and industry vertical

Which are the top PE firms investing in Vyriad's sector and industry vertical?

Top PE firms investing in Vyriad's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Vyriad's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Vyriad's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Vyriad's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Vyriad include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Vyriad's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Vyriad?

The key public trading comparables and valuation benchmarks for Vyriad include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Vyriad for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Vyriad with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Vyriad's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Vyriad with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Vyriad's' sector and industry vertical?

Access recent funding rounds and capital raises in Vyriad's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Vyriad